|1.||Fogari, Roberto: 11 articles (01/2011 - 07/2003)|
|2.||Mugellini, Amedeo: 9 articles (01/2011 - 07/2003)|
|3.||Zoppi, Annalisa: 7 articles (01/2008 - 07/2003)|
|4.||Rinaldi, Andrea: 5 articles (01/2008 - 07/2003)|
|5.||Lazzari, Pierangelo: 4 articles (01/2008 - 04/2005)|
|6.||Preti, Paola: 4 articles (01/2008 - 07/2003)|
|7.||Schmieder, Roland E: 3 articles (01/2013 - 04/2008)|
|8.||Alberici, Marco: 3 articles (01/2013 - 07/2003)|
|9.||Wenzel, René R: 3 articles (03/2009 - 01/2005)|
|10.||Fogari, R: 3 articles (10/2004 - 06/2000)|
|1.||Hypertension (High Blood Pressure)
01/01/1996 - "In conclusion, manidipine at an individualized dose of 10 or 20 mg. was effective and safe in the management of arterial hypertension. "
01/01/1992 - "Nephroprotective actions and other tissue protective effects of manidipine in the management of hypertension."
01/01/1996 - "Evaluation by 24-hour ambulatory blood pressure monitoring of efficacy of manidipine hydrochloride 10, 20 or 40 mg once daily as compared to placebo in treating mild to moderate essential hypertension: a double-blind, randomized, parallel group, placebo-controlled study."
01/01/2004 - "Thus, manidipine represents a first-line treatment option for patients with essential mild-to-moderate hypertension."
02/01/1993 - "Efficacy of manidipine in the treatment of hypertension with renal impairment: a multicenter trial."
12/01/1995 - "1. We evaluated the protective effects of manidipine on spermatogenic damage induced by the hypertensive vascular changes in stroke-prone spontaneously hypertensive rats (SHRSP). "
12/01/1995 - "Protective effects of manidipine on spermatogenesis in stroke-prone spontaneously hypertensive rats."
03/01/1997 - "Manidipine improves spermatogenesis in the stroke-prone spontaneously hypertensive rat."
11/01/1995 - "In the combination group and manidipine 2HCl-treated group, the neurological deficits after the onset of stroke were ameliorated during the entire experimentalperiod. "
02/01/1993 - "Furthermore, manidipine prevents the development of cerebrovascular lesions and inhibits the progression of vascular damage in the brain and kidneys of stroke-prone spontaneously hypertensive rats. "
|3.||Type 2 Diabetes Mellitus (MODY)
01/01/2004 - "Manidipine is also effective in hypertensive patients with comorbidities, such as type 2 diabetes mellitus and/or renal impairment, and appears to improve insulin sensitivity without affecting metabolic function. "
06/01/1996 - "This study confirmed the improving effects on SI and SG by long-term treatment with manidipine or delapril in the hypertensive NIDDM patients."
11/01/2011 - "Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial."
02/01/2000 - "Thirty-nine hypertensive patients with type 2 diabetes mellitus were followed under long-term treatment (mean, 20.7 months) with manidipine hydrochloride, a Ca antagonist, or delapril hydrochloride, an ACE inhibitor, at nine institutions. "
06/01/1996 - "Treatment with manidipine or delapril significantly reduced systolic and diastolic blood pressures in the hypertensive NIDDM patients. "
01/01/1992 - "These findings suggest that treatment with manidipine in DOCA/salt hypertensive rats lowered high blood pressure and improved impaired coronary circulation with a reduction in left ventricular and vascular hypertrophy."
01/01/1992 - "These results show that delapril and manidipine caused regression of hypertension-induced vascular hypertrophy in SHR. "
01/01/1992 - "These results suggest that manidipine has potent inhibitory effects on the ET-1-induced hyperplasia and/or hypertrophy of VSMC, as well as on the bFGF-induced hyperplasias of VSMC and EC, thus implicating its potential usefulness for preventing abnormal VSMC proliferation and angiogenesis associated with hypertension and atherosclerosis."
01/01/1992 - "The probable mechanism of regression of aortic hypertrophy by delapril was inhibition of vascular angiotensin II formation, but the mechanism for manidipine was unclear."
11/01/2001 - "Manidipine is an adequate, highly effective, exempt of metabolic effects and safe option for treatment of stage I and II essential hypertensive patients with overweight or android obesity."
11/01/2001 - "To evaluate the efficacy, metabolic effects and tolerability of manidipine used in the treatment of stage I and II essential hypertensive patients with overweight or android obesity. "
11/01/2001 - "[Manidipine in the treatment of stage I and II essential hypertension patients with overweight or android obesity. "
|9.||Calcium Channels (Calcium Channel)
|10.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
|1.||Sodium-Restricted Diet (Diet, Sodium Restricted)
|2.||Continuous Ambulatory Peritoneal Dialysis (CAPD)